Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
Andrew Blauvelt, Richard Langley, J.‐P. Lacour, et al.
Journal of the American Academy of Dermatology (2022) Vol. 87, Iss. 4, pp. 815-824
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 48
Optimal Use of Jak Inhibitors and Biologics for Atopic Dermatitis on the Basis of the Current Evidence
Masahiro Kamata, Yayoi Tada
JID Innovations (2023) Vol. 3, Iss. 3, pp. 100195-100195
Open Access | Times Cited: 43
Targeting IL‐13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years
Emma Guttman‐Yassky, Kenji Kabashima, D. Staumont‐Sallé, et al.
Allergy (2024) Vol. 79, Iss. 6, pp. 1560-1572
Open Access | Times Cited: 17
Real-Life Experience of Tralokinumab for the Treatment of Adult Patients with Severe Atopic Dermatitis: A Multicentric Prospective Study
Axel De Greef, Pierre‐Dominique Ghislain, Audrey Bulinckx, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 4, pp. 299-306
Open Access | Times Cited: 23
Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate‐to‐severe atopic dermatitis in adults: A multicentre real‐world study
Elena Pezzolo, Donatella Schena, Alessio Gambardella, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1
Closed Access | Times Cited: 22
A New Horizon for Atopic Dermatitis Treatments: JAK Inhibitors
Mircea Tampa, Cristina Iulia Mitran, Mădălina Irina Mitran, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 3, pp. 384-384
Open Access | Times Cited: 19
A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis
Katarzyna Waligóra-Dziwak, Aleksandra Dańczak‐Pazdrowska, Dorota Jenerowicz
Journal of Clinical Medicine (2024) Vol. 13, Iss. 14, pp. 4001-4001
Open Access | Times Cited: 8
Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 8, pp. 1983-2038
Open Access | Times Cited: 8
Atopic dermatitis: treatment and innovations in immunotherapy
Francesco Ferrara, Andrea Zovi, Maurizio Capuozzo, et al.
Inflammopharmacology (2024) Vol. 32, Iss. 3, pp. 1777-1789
Closed Access | Times Cited: 7
Emerging Systemic Treatments for Atopic Dermatitis
Silvia Ferrucci, Simona Tavecchio, Angelo Valerio Marzano, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 5, pp. 1071-1081
Open Access | Times Cited: 16
Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis
Joseph F. Merola, Daniel Butler, Thomas Mark, et al.
JAMA Dermatology (2023) Vol. 159, Iss. 10, pp. 1119-1119
Open Access | Times Cited: 15
Novel Therapeutic Targets for the Treatment of Atopic Dermatitis
Gaku Tsuji, Kazuhiko Yamamura, Koji Kawamura, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1303-1303
Open Access | Times Cited: 12
Cost-Effectiveness Analysis of Abrocitinib Compared with Other Systemic Treatments for Severe Atopic Dermatitis in Spain
Rosa María Romero Jiménez, Pedro Herranz, Minia Campos Domínguez, et al.
PharmacoEconomics - Open (2024) Vol. 8, Iss. 2, pp. 291-302
Open Access | Times Cited: 4
Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment
Joe Gorelick, Andrea Nguyen, Shannon Schneider, et al.
American Journal of Clinical Dermatology (2025)
Open Access
Effectiveness of Tralokinumab in Different Phenotypes of Atopic Dermatitis: A Real-World Study
Ersilia Tolino, Luca Ambrosio, Nicoletta Bernardini, et al.
Dermatology and Therapy (2025)
Open Access
What Does Long-Term Control in Atopic Dermatitis Look Like?
Shanthi Narla, Zelma C. Chiesa Fuxench, Katrina Abuabara, et al.
Dermatitis (2025)
Closed Access
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years
Raj Chovatiya, Simone Ribero, Andreas Wollenberg, et al.
American Journal of Clinical Dermatology (2025)
Open Access
Long-Term Stapokibart Treatment Induces Sustained Clinical Improvements in Patients With Moderate-to-Severe Atopic Dermatitis
Yan Zhao, Litao Zhang, Liming Wu, et al.
Dermatitis (2025)
Closed Access
Long-Term Efficacy and Potential Predictors of Tralokinumab Dose Optimization in Elderly Patients: A Multicentre Study
Francisco Javier Melgosa Ramos, Sergio Santos‐Alarcón, J.M. Sánchez Motilla, et al.
Dermatology and Therapy (2025)
Open Access
Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL‐13 inhibition
Eric L. Simpson, Emma Guttman‐Yassky, Lawrence F. Eichenfield, et al.
Allergy (2023) Vol. 78, Iss. 11, pp. 2875-2891
Open Access | Times Cited: 10
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review
Miguel Mansilla‐Polo, D. Morgado‐Carrasco
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1389-1442
Open Access | Times Cited: 3
Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?
Laura Marina Calabrese, Martina D’Onghia, Laura Lazzeri, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 7, pp. 775-775
Open Access | Times Cited: 3
Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years
Andrew Blauvelt, Vivian Laquer, Richard Langley, et al.
SKIN The Journal of Cutaneous Medicine (2025) Vol. 9, Iss. 2, pp. s573-s573
Open Access
First Short-Term Effectiveness and Security Data of Tralokinumab in Severe Atopic Dermatitis in Real Clinical Practice
Rubén García Castro, Felipe Heras Mendaza, Diana Inmaculada Santiago Sánchez-Mateos, et al.
Dermatitis (2023) Vol. 35, Iss. 3, pp. 301-303
Closed Access | Times Cited: 9
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials
Eric L. Simpson, Andrew Pink, Andrew Blauvelt, et al.
American Journal of Clinical Dermatology (2023) Vol. 24, Iss. 6, pp. 939-952
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top